ImageneBio (IMA) Price & Analysis

Compare

109 Followers

IMA Stock Chart & Stats

$6.64

Market closed

$6.64

Day’s Range― - ―

52-Week Range$5.70 - $18.11

Previous CloseN/A

VolumeN/A

Average Volume (3M)69.52K

Market Cap

$74.61M

Enterprise Value-$18.18M

Total Cash (Recent Filing)$142.58M

Total Debt (Recent Filing)$10.96M

Price to Earnings (P/E)―

Beta0.68

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding11,181,672

10 Day Avg. Volume58,561

30 Day Avg. Volume69,515

Financial Highlights & Ratios

PEG Ratio0.69

Price to Book (P/B)7.54

Price to Sales (P/S)271.35

P/FCF Ratio-20.64

Enterprise Value/Market Cap-0.24

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit2.18

Enterprise Value/Ebitda0.33

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-4.01

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Cash PositionA strong cash position provides financial flexibility, allowing Ikena Oncology to invest in R&D and navigate periods of low revenue without immediate liquidity concerns.

Proprietary PlatformIkena's proprietary platform for targeted oncology treatments positions it to potentially develop breakthrough therapies, offering a competitive edge in the biotech industry.

Low Debt LevelsLow debt levels reduce financial risk and interest obligations, allowing more resources to be allocated towards strategic growth initiatives and R&D.

Bears Say

Declining RevenuesThe absence of revenue growth poses a significant challenge, limiting the company's ability to fund operations and invest in future growth without external financing.

Negative Cash FlowNegative cash flow indicates ongoing cash burn, necessitating reliance on external funding, which can dilute shareholder value and increase financial risk.

Profitability ChallengesContinuous profitability challenges hinder the company's ability to self-sustain, impacting its long-term viability and attractiveness to investors.

ImageneBio News

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/25/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up 0.34% in...

6d ago

CLB

VTI ETF Inflows Hold Steady Despite AI Sell-Off – 2/24/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is down 0.086% in...

7d ago

CLB

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/23/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up 0.94% in...

8d ago

CLB

IMA

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/20/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up 0.50% in...

11d ago

CLB

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/19/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is down 0.26% in...

12d ago

CLB

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/16/26

The Vanguard Total Stock Market ETF ($VTI) tracks the broader U.S. stock market. VTI’s three-month average trading volume...

15d ago

IMA

Vanguard Total Stock Market ETF (VTI) Daily Update—2/13/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up 0.38% in...

18d ago

IMA

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/12/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is down 0.24% in...

19d ago

CLB

IMA

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/11/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up 0.56% in...

20d ago

CLB

ImageneBio appoints Ben Porter-Brown as Chief Medical Officer

ImageneBio (IMA) announced the appointment of Dr. Ben Porter-Brown as its Chief Medical Officer. He will be focused...

21d ago

IMA

ImageneBio announces immediate resignation of board director

ImageneBio ( ($IMA) ) has provided an announcement. On February 12, 2026, ImageneBio, Inc. announced that Steven Hui...

14d ago

IMA

ImageneBio assumed at Underperform from Neutral at Wedbush

Wedbush analyst Martin Fan downgraded ImageneBio (IMA) to Underperform from Neutral with a price target of $2, down...

3M ago

IMA

ImageneBio reports Q3 EPS ($2.91) vs. ($2.58) last year

Reports Q3 revenue $0 vs. $3.5M last year. “We are in a wonderful position as we complete our...

4M ago

IMA

ImageneBio initiated with an Outperform at Leerink

Leerink initiated coverage of ImageneBio (IMA) with an Outperform rating and $30 price target. The firm views shares...

4M ago

IMA

SNY

IMA FAQ

What was ImageneBio’s price range in the past 12 months?

ImageneBio lowest stock price was $5.70 and its highest was $18.11 in the past 12 months.

What is ImageneBio’s market cap?

ImageneBio’s market cap is $74.61M.

When is ImageneBio’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were ImageneBio’s earnings last quarter?

ImageneBio released its earnings results on Aug 07, 2025. The company reported -$0.688 earnings per share for the quarter, missing the consensus estimate of -$0.33 by -$0.358.

Is ImageneBio overvalued?

According to Wall Street analysts ImageneBio’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ImageneBio pay dividends?

ImageneBio does not currently pay dividends.

What is ImageneBio’s EPS estimate?

ImageneBio’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ImageneBio have?

ImageneBio has 11,181,672 shares outstanding.

What happened to ImageneBio’s price movement after its last earnings report?

ImageneBio reported an EPS of -$0.688 in its last earnings report, missing expectations of -$0.33. Following the earnings report the stock price went down -0.697%.

Which hedge fund is a major shareholder of ImageneBio?

Currently, no hedge funds are holding shares in IMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

ImageneBio Stock Smart Score

Underperform

Fundamentals

Return on Equity

-33.05%

Trailing 12-Months

Asset Growth

-19.89%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ImageneBio

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis